Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by Xponance Inc.

Xponance Inc. boosted its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 3.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,676 shares of the biopharmaceutical company’s stock after buying an additional 163 shares during the period. Xponance Inc.’s holdings in Intra-Cellular Therapies were worth $407,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Quantum Private Wealth LLC increased its position in Intra-Cellular Therapies by 64.7% during the 4th quarter. Quantum Private Wealth LLC now owns 23,705 shares of the biopharmaceutical company’s stock valued at $1,698,000 after buying an additional 9,308 shares in the last quarter. HealthInvest Partners AB purchased a new stake in Intra-Cellular Therapies during the 4th quarter valued at about $877,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Intra-Cellular Therapies by 36.1% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,738 shares of the biopharmaceutical company’s stock valued at $1,342,000 after purchasing an additional 4,974 shares during the last quarter. Mackenzie Financial Corp purchased a new stake in Intra-Cellular Therapies during the 4th quarter valued at about $289,000. Finally, Phocas Financial Corp. purchased a new stake in Intra-Cellular Therapies during the 4th quarter valued at about $1,949,000. 92.33% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Intra-Cellular Therapies news, CFO Lawrence J. Hineline sold 13,337 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $69.43, for a total transaction of $925,987.91. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Intra-Cellular Therapies news, CFO Lawrence J. Hineline sold 13,337 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $69.43, for a total transaction of $925,987.91. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Sharon Mates sold 20,565 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $65.21, for a total value of $1,341,043.65. Following the transaction, the chief executive officer now directly owns 1,050,309 shares of the company’s stock, valued at approximately $68,490,649.89. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 168,487 shares of company stock worth $11,364,950. 3.40% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

ITCI has been the topic of several research analyst reports. TD Cowen boosted their price target on Intra-Cellular Therapies from $80.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. Robert W. Baird boosted their price target on Intra-Cellular Therapies from $83.00 to $103.00 and gave the company an “outperform” rating in a research note on Wednesday, April 17th. The Goldman Sachs Group boosted their price target on Intra-Cellular Therapies from $67.00 to $77.00 and gave the company a “neutral” rating in a research note on Wednesday, April 17th. Royal Bank of Canada reiterated an “outperform” rating and set a $86.00 price target on shares of Intra-Cellular Therapies in a research note on Wednesday, April 3rd. Finally, Canaccord Genuity Group upped their target price on Intra-Cellular Therapies from $100.00 to $107.00 and gave the stock a “buy” rating in a research note on Tuesday, April 23rd. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Intra-Cellular Therapies currently has a consensus rating of “Moderate Buy” and a consensus price target of $90.17.

Intra-Cellular Therapies Stock Up 1.6 %

Shares of ITCI opened at $73.26 on Friday. The company has a market capitalization of $7.09 billion, a price-to-earnings ratio of -50.18 and a beta of 1.02. The stock’s 50-day moving average price is $69.33 and its 200-day moving average price is $64.85. Intra-Cellular Therapies, Inc. has a 52 week low of $45.50 and a 52 week high of $84.89.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.14. The company had revenue of $132.10 million for the quarter, compared to the consensus estimate of $135.97 million. Intra-Cellular Therapies had a negative return on equity of 23.02% and a negative net margin of 30.08%. Intra-Cellular Therapies’s revenue for the quarter was up 50.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.45) earnings per share. As a group, equities analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.59 EPS for the current fiscal year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.